康方生物再次转亏,为何市场看好?

远见资本局
07 Apr

出品|远见资本局作者|远见君3月30日晚,康方生物发布了2024年业绩报告。财报显示,康方生物报告期内实现营收21.40亿元,同比下滑53.08%;实现归属股东应占溢利-5.145亿元人民币,较上年由盈利转为亏损。从业绩表现来看,康方生物出现了较大的退步,但是市场却对康方生物青睐有加。3月31日,康方生物股价上涨2.14%,4月1日涨幅更是达到12.86%,至4月3日出现一定回落,报收85.90...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10